Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) shares gapped down prior to trading on Thursday. The stock had previously closed at $31.43, but opened at $29.73. Spyglass Pharma shares last traded at $28.47, with a volume of 5,982 shares changing hands.
Analyst Upgrades and Downgrades
SGP has been the topic of several recent analyst reports. UBS Group reaffirmed a "buy" rating on shares of Spyglass Pharma in a research report on Monday, October 5th. Wall Street Zen raised Spyglass Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, October 31st. Stifel Nicolaus raised their price objective on shares of Spyglass Pharma from $42.00 to $44.00 and gave the stock a "buy" rating in a research note on Friday, November 13th. Weiss Ratings raised shares of Spyglass Pharma from a "sell (e)" rating to a "sell (d-)" rating in a research report on Friday, November 13th. Finally, Citigroup boosted their target price on shares of Spyglass Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday, November 13th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $45.83.
Get Our Latest Analysis on SGP
Spyglass Pharma Stock Down 3.8%
The stock's 50-day moving average price is $28.94 and its 200 day moving average price is $24.92. The firm has a market cap of $955.48 million and a price-to-earnings ratio of -3.69.
Spyglass Pharma (NASDAQ:SGP - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.07). On average, research analysts predict that Spyglass Pharma, Inc. will post -2.77 EPS for the current year.
Insider Activity at Spyglass Pharma
In other news, Director Ra Capital Management, L.P. bought 1,000 shares of the business's stock in a transaction that occurred on Monday, November 16th. The stock was acquired at an average cost of $32.43 per share, for a total transaction of $32,430.00. Following the completion of the purchase, the director owned 5,967,439 shares of the company's stock, valued at $193,524,046.77. This trade represents a 0.02% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Hedge Funds Weigh In On Spyglass Pharma
Hedge funds and other institutional investors have recently made changes to their positions in the business. First Light Asset Management LLC acquired a new stake in shares of Spyglass Pharma during the 1st quarter valued at about $9,716,000. Affinity Asset Advisors LLC bought a new position in Spyglass Pharma during the first quarter worth about $6,478,000. Monashee Investment Management LLC bought a new position in Spyglass Pharma during the first quarter worth about $2,461,000. Bank of America Corp DE bought a new position in Spyglass Pharma during the first quarter worth about $726,000. Finally, Bank of New York Mellon Corp acquired a new stake in Spyglass Pharma during the second quarter valued at approximately $533,000.
About Spyglass Pharma
(
Get Free Report)
SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients' regular use of eye drops. The company's lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma's work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Spyglass Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyglass Pharma wasn't on the list.
While Spyglass Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.